8-KMaterial AgreementsFinancial Events

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Jan 13, 2011)

Filed January 13, 2011For Securities:VRTX

Summary

Vertex Pharmaceuticals Incorporated (VRTX) announced on January 7, 2011, that it has entered into a credit agreement with Bank of America, N.A. This agreement establishes a $100 million revolving credit facility, which is initially unsecured. As of the filing date, Vertex was not drawing on this facility, indicating a precautionary measure or potential future need for liquidity. The credit facility has a maturity date of July 6, 2012, and allows for borrowings at either LIBOR plus 1.50% or Bank of America's prime rate. Key covenants within the agreement require Vertex to maintain a minimum of $400 million in cash, cash equivalents, and marketable securities and also impose limitations on quarterly net losses. The agreement includes standard representations, warranties, covenants, and events of default. The obligation to borrow is subject to satisfactory due diligence by the lender.

Key Highlights

  • 1Vertex Pharmaceuticals entered into a $100 million revolving credit facility with Bank of America.
  • 2The credit facility is initially unsecured and was not being utilized as of the filing date.
  • 3The facility has a term until July 6, 2012.
  • 4Interest rates for borrowings will be based on LIBOR plus 1.50% or Bank of America's prime rate.
  • 5The agreement includes covenants requiring Vertex to maintain at least $400 million in cash, cash equivalents, and marketable securities.
  • 6There are limitations on the company's quarterly net losses.
  • 7The facility may become secured by cash, cash equivalents, and marketable securities upon certain defaults.

Frequently Asked Questions

The filing indicates the credit facility is a revolving credit line of $100 million. While not being borrowed against at the time of filing, such facilities are typically established for general corporate purposes, to provide financial flexibility, or as a precautionary measure to ensure access to capital if needed for operations, investments, or unexpected events.

The credit agreement requires Vertex to maintain a minimum of $400 million in cash, cash equivalents, and marketable securities. It also limits the company's quarterly net losses. Additionally, the lender's obligation to provide funds is subject to satisfactory due diligence, and certain corporate actions like significant investments or debt prepayments could affect Vertex's ability to borrow.

In the event of a default, particularly a financial covenant default, the loans will become secured by Vertex's cash, cash equivalents, and marketable securities valued at $100 million. An event of default could also lead to an increased interest rate and the acceleration of all amounts due under the loan, allowing the agent to take various enforcement actions.

The credit facility has a term that allows Vertex to borrow, repay, and reborrow funds until July 6, 2012, at which point the facility will terminate.